Format

Send to

Choose Destination
Cancer Lett. 2019 Aug 28;458:29-38. doi: 10.1016/j.canlet.2019.05.028. Epub 2019 May 23.

IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas.

Author information

1
Brain Tumour Research Centre, Institute of Biomedical and Biomolecular Sciences, IBBS, University of Portsmouth, PO1 2DT, UK.
2
Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Building 8, Room 3.4, 8005-139, Faro, Portugal.
3
Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, L69 3GE, UK.
4
Brain Tumour Research Centre, Institute of Biomedical and Biomolecular Sciences, IBBS, University of Portsmouth, PO1 2DT, UK. Electronic address: richard.hill@port.ac.uk.

Abstract

High grade gliomas (HGGs) are aggressive primary brain tumours with local invasive growth and poor clinical prognosis. Clinical outcome is compounded by resistance to standard and novel therapeutics. We have evaluated reformulated aspirin (IP1867B) alone and in combination with conventional and novel anti-aHGG agents. We show that recent biopsy-derived aHGG models were highly resistant to conventional therapeutics although show sensitivity to IP1867B, a reformulated "liquid" aspirin. IP1867B treatment mediated a potent suppression of the IL6/STAT3 and NF-κB pathways and observed a significant reduction in EGFR transcription and protein expression. We observed the loss of the insulin-like growth factor 1 and insulin-like growth factor 1 receptor expression at both the transcript and protein level post IP1867B treatment. This increased sensitivity to EGFR inhibitors. In vivo, IP1867B was very well tolerated, had little-to-no gastric lesions versus aspirin and, directed a significant reduction of tumour burden with suppression of EGFR, IGF1 and IGFR1. With EGFR inhibitors, we noted a potent synergistic response in aHGG cells. These data provide a rationale for further investigation of IP1867B with a number of anti-EGFR agents currently being evaluated in the clinic.

KEYWORDS:

Adult high grade glioma; Drug repurposing; EGFR; IGFR1

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center